EP
ANAB icon

Essential Partners’s AnaptysBio ANAB Stock Holding History

Essential Partners’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15K Sell
17
-16
-48% -$970 ﹤0.01% 2183
2026
Q1 		$1.83K Hold
33
– – ﹤0.01% 2042
2025
Q4 		$1.6K Hold
33
– – ﹤0.01% 1872
2025
Q3 		$1.01K Hold
33
– – ﹤0.01% 2018
2025
Q2 		$733 Buy
+33
New +$691 ﹤0.01% 1588

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Essential Partners's ANAB Position: Q2 2026 in Review

Essential Partners reduced its AnaptysBio (ANAB) stake by 48% in Q2 2026, selling an estimated $970 and leaving 17 shares worth $1.15K. The position accounts for ﹤0.01% of the portfolio, ranked #2183.

Essential Partners first reported a position in ANAB in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.83K in Q1 2026. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Essential Partners held 17 shares of AnaptysBio worth $1.15K as of Q2 2026.
  • Essential Partners sold 16 AnaptysBio shares in Q2 2026, an estimated $970.
  • AnaptysBio made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2183 holding.
  • Essential Partners first reported a position in AnaptysBio in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's AnaptysBio position peaked at $1.83K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.